Acelot to Present ALS Research at NEALS Meeting
Representatives from the biotech firm will discuss drug development and therapeutic targets in Clearwater this October.
Updated on Oct. 26, 2026 in Alzheimer’s
Acelot is set to present new research at the 2026 annual NEALS meeting taking place from October 27 to October 30, 2026, in Clearwater, Florida. The company will showcase its progress in targeting aggregated TDP-43 for the treatment of sporadic ALS.
Why it matters
The upcoming presentations highlight Acelot's ongoing efforts to advance therapeutic options for ALS patients through its computational drug discovery work. These sessions aim to provide insights into how modern technology is being applied to identify and develop new treatments for neurodegenerative conditions.
Acelot utilizes its proprietary RESOLUTE AI computational chemistry platform to integrate physics-based and AI models for drug development. The company currently focuses on targeting aggregated TDP-43 proteins to address sporadic ALS.
The players
Acelot
A South San Francisco-based biotechnology company that utilizes advanced computational chemistry platforms to develop small molecule drugs.
Katie Planey
The Chief Executive Officer of Acelot who will engage in industry discussions regarding therapeutic targets during the NEALS conference.
Mark Forman
The Chief Medical Officer of Acelot who will present preclinical data concerning the company's TDP-43 program at the 2026 meeting.
The details
The South San Francisco-based company will share findings from its TDP-43 program during the meeting. Experts from the firm will participate in both an oral presentation and an industry roundtable to discuss their approach to therapeutic targets in this field.
Timeline
The 2026 Annual NEALS meeting runs from October 27 to October 30, 2026.
CEO Katie Planey will participate in a panel discussion on October 28, 2026, at 3:30 PM ET.
CMO Mark Forman is scheduled to deliver an oral presentation on October 30, 2026, at 11:40 AM ET.
The Big Picture
The presentation of Acelot's ALS research at the NEALS annual research meeting reflects a standard step for biotech firms sharing developments in the field. This event follows the pattern set by the NEALS annual research meeting in providing a platform for firms to disclose new scientific findings.
The research presented could eventually expand the available treatment options for patients diagnosed with sporadic ALS. While currently at the preclinical stage, these developments represent the early steps toward potential future clinical interventions.
The takeaway
Advancements in computational chemistry are increasingly central to modern drug discovery efforts in neurodegenerative diseases. Keeping track of emerging research schedules can help stakeholders monitor the progress of new therapeutic programs.
Further reading
For more information on current developments, visit the Alzheimer’s section of our site.
Source note: This article includes information reported by Firstwordpharma.
